AbbVie Inc. Common Stock — Filings & Documents (NYSE:ABBV) — Page 26 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends Documents

2012

Current report, 14 Dec 2012

Abbvie Inc. current report, 14 December 2012

News

S&P 500 Top Stock Gainers Today, 10/13/26 - TipRanks.com

AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment

Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails

RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

Why A Biotech M&A Wave May Hit This Winter

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?

Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s

Wall Street Bruch: Start Your Earnings Engines (NYSE:JPM)

The Week That Was, The Week Ahead: Macro and Markets, October 11 - TipRanks.com

Banking Bellwethers Kick Off Earnings, Fed's Warsh's Speech In Focus